enGene Therapeutics Inc. Common Stock
ENGNStock
$1.92−45.87%52W
Market Cap$127.28M
P/E—
Div yield—
Beta-0.30
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-87.11%
Price vs S&P 500 (4W)7.97%
VGM Score24.46
Market Capitalization$127.28M
Earnings Surprise History
Q2 26-0.43est. -0.48
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
4.32
3.74
3.72
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENGNenGene Therapeutics Inc. Common Stock | — | — | D | $1.92 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
enGene Holdings is a clinical-stage biotech company developing localized gene therapies using its proprietary non-viral DDX delivery platform. The company is initially targeting non-muscle invasive bladder cancer (NMIBC) and aims to expand to other high-need diseases through direct delivery to mucosal tissues and organs.